ALMR financial statements
The full income statement, balance sheet, and cash-flow statement for Alamar Biosciences Inc. (ALMR), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
| Line item | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Income Statement | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| Revenue | 29.4M | 26.0M | |
| 17.7M | 14.5M | ||
| Cost of revenue | 11.7M | 11.6M | |
| 31.3M | 26.8M | ||
| Research & development | 13.8M | 13.0M | |
| Selling, general & administrative | 17.4M | 13.8M | |
| Operating income | -13.5M | -12.3M | |
| Interest & investment income | 1.88M | 539K | |
| Pre-tax income | -13.3M | -20.9M | |
| Income tax | -93.0K | 464K | |
| Net income | -13.2M | -21.3M | |
| -$0.22 | -$1.74 | ||
| EPS (basic) | -$0.22 | -$1.74 | |
| Weighted-avg shares (basic) | 58.7M | 12.3M | |
| Weighted-avg shares (diluted) | 58.7M | 12.3M | |
| Balance Sheet | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| 331M | 141M | ||
| Cash & equivalents | 133M | 64.6M | |
| Short-term investments | 117M | 0.00 | |
| Accounts receivable | 20.3M | 19.5M | |
| Inventory | 45.4M | 39.9M | |
| Prepaid expenses | 15.6M | 17.4M | |
| 391M | 186M | ||
| Property, plant & equipment | 13.4M | 10.5M | |
| Operating lease right-of-use | 35.8M | 25.7M | |
| Long-term investments | — | 0.00 | |
| Other non-current assets | 2.58M | 2.09M | |
| 28.0M | 24.0M | ||
| Accounts payable | 13.8M | 5.63M | |
| Deferred revenue | 2.19M | 2.11M | |
| Current lease liability | 2.28M | 1.60M | |
| 78.1M | 130M | ||
| Non-current lease liability | 39.2M | 29.0M | |
| Operating lease liability (total) | 41.5M | 30.6M | |
| Other non-current liabilities | 1.03M | 1.20M | |
| 313M | -178M | ||
| Common stock | 7.00K | 1.00K | |
| Additional paid-in capital | 516M | 12.1M | |
| Retained earnings | -203M | -190M | |
| Accumulated other comprehensive income | -139K | -80.0K | |
| Total equity incl. non-controlling | 313M | -178M | |
| Total liabilities & equity | 391M | 186M | |
| Shares outstanding (cover) | 69.4M | 69.3M | |
| Cash Flow | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| -11.3M | -20.3M | ||
| Depreciation & amortization | 1.13M | 1.17M | |
| Share-based compensation | 3.28M | 1.47M | |
| Change in receivables | 967K | 6.85M | |
| Change in inventory | 5.72M | 1.26M | |
| Change in payables | 6.32M | 1.34M | |
| -121M | -778K | ||
| Capital expenditure | 3.64M | 600K | |
| Free cash flow | -15.0M | -20.9M | |
| Acquisitions | 0.00 | 0.00 | |
| 202M | 55.8M | ||
| Long-term debt issued | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | |
| Common stock issued | 205M | 0.00 | |
| Common stock repurchased | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | |
| Net change in cash | 69.7M | 34.6M | |
| Interest paid | 147K | 156K | |
| Valuation Ratios | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| Market cap | 1.59B | — | |
| P/B | 5.1× | — | |
| Source filing | 10-Q | 10-Q |
About this data
Source: ALMR’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all ALMR filings on SEC EDGAR → Not investment advice.